Keshav Bhutada becomes CEO of Shilpa Pharma Life Sciences

“SPL is a strong organization with some of the best talent in the industry and a leader in APIs, polymers, and peptides. It also stands out as one of the most integrated platforms in the CDMO space. Keshav is a capable and visionary leader who will take the company forward. As I continue my professional journey outside this organization, I extend my best wishes to the entire SPL team and Keshav for continued success,” said Mahil.

As part of the overall re-organisation of group responsibilities, Madhav Bhutada has been assigned the responsibility to oversee the Group’s biologics foray spearheading the Recombinant Albumin & large-scale microbial fermentation facility operations. He also plays a pivotal role in steering growth of biosimilars vertical, contributing to selection of a robust pipeline and actively engaging in fast growing CDMO Biologics business.